Peptides DB
Research-centric peptide and protocol reference hub

Setmelanotide record · updated 6h ago

Metabolic & appetiteSkin & aestheticsGrade A · human clinicalResearch use only
All 17 studiesJump to the evidenceCompare
What is Setmelanotide used for?

Research peptide discovered via AI researcher. peptide-based therapeutic

How it works: MC4R agonist

Primarily researched for · Metabolic & appetiteRoute · Subcutaneous injection

Development stage

where Setmelanotide sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 30 registered trials. It describes the research record, not a recommendation.

Identity
NameSetmelanotide
Chain length—
Molecular weight1,117.3 Da
FormulaC49H68N18O9S2
Structure typeNot established
ClassMetabolic
Research levelFDA Approved
Discovered byThe Librarian · 2026

Mass and formula from PubChem CID 11993702. No verified residue count for this compound.

Pharmacology
MechanismMC4R agonist
RouteSubcutaneous injection
Half-life~7 hours
Time to peak1–2 hours
Duration—
Extraction confidence0.80
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 9, 2026. How this works →
Research stats
Total studies17
Human / animal / cellular11 / 1 / 1
Highest trial phasePhase 3
Years covered2023–2026
Latest study12d ago
Publication history
20232026
Research funding
37 NIH projects · $28.7M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reports164
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

17 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Positioning Incretin-Based and Next-Generation Obesity Management Medications: A Methodological Framework for a Series of Systematic Reviews and Network Meta-Analyses.
FindingNot reported in abstract.
review2026Full text read0.70
Effectiveness and Safety of Setmelanotide in a Patient With a Heterozygous PCSK1 Deficiency.
Finding11.8% total weight loss over 3 months
Human2026Full text read0.70
Global genomics in over 4 million individuals prioritizes therapeutic targets for heart failure and its subtypes
FindingIdentified 383 loci associated with heart failure, n=4,468,166.
Human2026Full text read0.80
Discovery of TL10: A Soluble and Long-Acting MC4R Agonist with Tunable Lipidation for Sustained Pharmacological Activity.
Findingt1/2 ≈ 33.4 h for TL10, a 34-fold increase compared to setmelanotide.
Animal—Full text read0.80
Goldilocks-Inspired Design of Mid-Size Macrocycles for Selective Targeting of Human Melanocortin Receptors.
FindingNot reported in abstract.
Human—Full text read0.70
Industrial-scale production of basil hairy roots in a 1000-L bioreactor and advanced downstream processing for the preparation of cosmetic ingredients.
Finding96.4 kg of biomass fresh weight within 84 days.
In vitro2026Full text read0.70
Real-World Spinal Cord Stimulation Utilization and Implant Status: An Analysis of a Novel, Real-Time, Remote Monitoring Database.
Finding95.1% remained implanted at a median SCS implant duration of 364 days, n=493.
Human2025Full text read0.80
Adverse event profile of setmelanotide in obesity: an integrated assessment and systematic review using disproportionality analysis, case reports and meta-analysis.
Finding96% injection-site reactions, 95% CI: 89, 100, n=185.
review2025Full text read0.90
Human HYPOMAP: A comprehensive spatio-cellular map of the human hypothalamus
Finding182 neuronal clusters significantly enriched in expression of BMI GWAS genes.
Human2023Full text read0.80
Inversed impaired osteogenic activity in children with severe obesity due to MC4R deficiency compared to LEP and LEPR deficiency
FindingSerum osteocalcin and osteopontin levels were significantly lower in subjects with LEP and LEPR biallelic variants compared to controls, p<0.001.
Human2025Full text read0.80
Setmelanotide for the Treatment of Acquired Hypothalamic Obesity.
FindingLSM change in BMI at 52 weeks was -16.5% (95% CI, -19.3 to -13.8) with setmelanotide and 3.3% (95% CI, -0.6 to 7.2) with placebo (P<0.001)
Human2023Full text read0.90
Respiratory Adverse Events of Weight-Loss Drugs: A Systematic Review and Meta-Analysis.
FindingNasopharyngitis incidence ranged from 4.1% (95% CI: 0.7%, 9.3%; tirzepatide, 0-6 months) to over 23.7% (95% CI: 19.6%, 28.1%; liraglutide, 13-24 months).
review2023Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Setmelanotide will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Setmelanotide is discussed should be drawn from it.